Genomic Health Anticipates Breast Cancer Test Growth in Europe, Preps More Data on Prostate Assay | GenomeWeb

Originally published May 13.

NEW YORK (GenomeWeb) — Genomic Health said that it anticipates continued adoption of its flagship Oncotype DX breast cancer test outside the US this year, and it is planning to share several studies in coming months supporting the expanded use of that test. Company officials also discussed during a call describing first quarter earnings last week efforts to build the evidence base for, and drive adoption of, its new prostate cancer diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.